Podcasts about Drug development

  • 509PODCASTS
  • 1,549EPISODES
  • 32mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jun 15, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Drug development

Show all podcasts related to drug development

Latest podcast episodes about Drug development

Invest Like the Best with Patrick O'Shaughnessy
Dinakar Singh - A Father's Call To Action - [Invest Like the Best, EP.428]

Invest Like the Best with Patrick O'Shaughnessy

Play Episode Listen Later Jun 15, 2025 46:49


My guest today is Dinakar Singh. Dinakar is the founder and CEO of Axon, the family office successor to TPG-Axon, which was a successful global long-short hedge fund. We wanted to share his story on Father's Day to honor the person and the dad that Dinakar is. He shares one of the most extraordinary stories at the intersection of finance and medicine I've ever encountered. This conversation explores the highest-stakes investment themes—timing, concentrated conviction, exceptional team building, and deploying resources toward outcomes that matter most. I will let him tell you his story. Please enjoy my conversation with Dinakar Singh.  For the full show notes, transcript, and links to mentioned content, check out the episode page⁠⁠⁠ here.⁠⁠⁠ ----- This episode is brought to you by⁠⁠⁠ Ramp⁠⁠⁠. Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠ Ramp.com/invest⁠⁠⁠ to sign up for free and get a $250 welcome bonus. – This episode is brought to you by⁠⁠⁠ Ridgeline⁠⁠⁠. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Head to⁠⁠⁠ ridgelineapps.com⁠⁠⁠ to learn more about the platform. – This episode is brought to you by⁠⁠⁠ AlphaSense⁠⁠⁠. AlphaSense has completely transformed the research process with cutting-edge AI technology and a vast collection of top-tier, reliable business content. Invest Like the Best listeners can get a free trial now at⁠⁠⁠ Alpha-Sense.com/Invest⁠⁠⁠ and experience firsthand how AlphaSense and Tegus help you make smarter decisions faster. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠). Show Notes: (00:00:00) Welcome to Invest Like the Best (00:06:17) The Diagnosis and Initial Reactions (00:07:29) Understanding SMA and the Scientific Challenge (00:09:15) The Drive to Fund Research and Find a Cure (00:14:10) Building a Virtual Company for Drug Development (00:19:02) Breakthroughs and the First Approved Drugs (00:24:16) Personal Reflections and the Impact of the Journey (00:40:25) Challenges in the Biotech Industry and Future Hopes (00:46:43) The Kindest Thing Anyone Has Ever Done For Dinakar

Raise the Line
The Importance of Seeing Rare Disease Patients Holistically: Eric & Kristi Levine, Parents of a Child with CACNA1A

Raise the Line

Play Episode Listen Later Jun 12, 2025 27:47


"It was pretty apparent to me that something was going on with him," says Kristi Levine, describing the realization that, based on her experience as a Montessori teacher, her infant son, Trey, was missing developmental milestones. Unfortunately, Kristi's hunch turned out to be correct and Trey was later diagnosed with a rare genetic mutation called CACNA1A which is impacting his motor skills, balance, coordination and speech. Kristi and her husband, Eric, join host Michael Carrese on this installment in our Year of the Zebraseries to help us understand the disorder and its implications for Trey and their family, which includes Trey's older sister Stella.  “There's a lot of guilt involved in being a parent of a child who has a disability because you never feel like you're doing enough,” shares Eric, even though they both work full time and have becoming experts at juggling work, caregiving, advocating, and volunteering with the CACNA1A Foundation. In this candid interview, Eric and Kristi discuss the challenges of parenting a child with complex medical needs, the importance of community support, the ongoing search for treatment options, and share some advice for clinicians caring for patients and families living with rare disorders. “We just want medical professionals to respect and understand what we're dealing with on a day-to-day basis and to see our kids holistically, and not just try to fix the problem medically. Understand that for us, the biggest thing that we want for our kids is just their quality of life.”Mentioned in this episode:CACNA1A Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

ACRO's Good Clinical Podcast
S3: E8 AI on the Prize: How AI is Modernizing Clinical Operations

ACRO's Good Clinical Podcast

Play Episode Listen Later Jun 10, 2025 32:08


In this episode, Jonathan Norman (Director, Localisation Services, YPrime) and Laura Russell (Senior Vice President, Head of Data and AI Product Development, Advarra) join the podcast to discuss how artificial intelligence is transforming today's clinical operations. They dive deeper into how AI can be used to improve protocol design, drive efficiency in localization processes, and modernize clinical operations to expand access to trials and get treatments to patients sooner. 

Artificial Intelligence in Industry with Daniel Faggella
Leveraging Data to Scale Drug Development Globally - with Damion Nero of Takeda

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Jun 5, 2025 29:26


Today's guest is Damion Nero, Head of Data Science at Takeda Pharmaceuticals. With over 15 years of experience applying AI, machine learning, and real-world data to drug development and precision medicine, Damion joins Emerj Managing Editor Matthew DeMello to explore the evolving role of AI in drug development and supply chain management. He breaks down how AI is currently streamlining administrative and regulatory tasks, improving efficiency across clinical trials, and saving valuable time for healthcare professionals. Damion also discusses why broader, transformative supply chain efficiencies are still on the horizon, as AI continues to evolve and scale in the pharmaceutical industry. This episode is sponsored by Arkestro. Learn more about Arkestro's upcoming Advisory Council event here. Find out more about sponsored content and how to engage with the Emerj audience at emerj.com/ad1.

RARECast
How One Patient Organization Drives Drug Development

RARECast

Play Episode Listen Later Jun 5, 2025 49:19


The Children's Tumor Foundation has been effective in working with drug developers to advance new therapies for neurofibromatosis, a group of rare, genetic conditions that cause tumors to grow on nerves throughout the body. Part of its success has been its ability to get biopharmaceutical companies to reposition assets once in development for other conditions as potential treatments for neurofibromatosis. We spoke to Annette Bakker, CEO of the Children's Tumor Foundation, about the complexities of neurofibromatosis, the foundation's role in advancing research and drug development, and what other patient organizations can learn from its strategic approach.

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Jun 4, 2025 29:54


Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA.     Timestamps  01:44 – Quickfire questions  07:25 – CAR-T cell therapy  10:48 – Anti-CD38 antibodies  13:31 – Minimal residual disease  14:30 – Bispecific antibodies  15:31 – Antibody-drug conjugates  19:04 – ASCO 2025  21:24 – Genetic discoveries  26:28 – Fonseca's three wishes 

Sounds of Science
Behind the Breakthroughs: Rethinking Animal Research with the 3Rs

Sounds of Science

Play Episode Listen Later Jun 3, 2025 44:25


What happens when cutting-edge science meets compassion? In this episode of Sounds of Science, host Mary Parker sits down with two pioneers reshaping the future of research: Elizabeth Nunamaker, Executive Director of Global Animal Welfare and Training at Charles River, and Dr. Megan LaFollette, Executive Director of the 3Rs Collaborative. From digital biomarkers to environmental health monitoring, they reveal how innovation and collaboration are redefining what's possible in animal welfare — and raising the bar for ethical, high-quality research. Tune in to explore the tools, strategies, and bold ideas driving meaningful change across the scientific community.Show NotesAdvancing Alternatives | Charles RiverEvolving Animal Welfare: Science, Ethics, and Innovation | Sounds of Science Can You Practice High-quality Science and 3Rs? | Eureka BlogAnimals in Research | Charles RiverResearch Models & Services | Charles River

ACRO's Good Clinical Podcast
S3: E7 The Impact of ICH E6(R3): Sponsor and CRO Perspectives

ACRO's Good Clinical Podcast

Play Episode Listen Later Jun 3, 2025 26:11


In the latest collaboration between ACRO and TransCelerate BioPharma, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week's episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. They dive deeper into their experiences implementing the new guidance at their respective companies, the new opportunities that R3 has created in the partnership between CROs and sponsors, and how they envision the future state of R3 once industry has fully embraced the guidance. FIND ACRO & TRANSCELERATE'S ICH E6(R3) TOOLS & RESOURCES HERE: https://www.acrohealth.org/initiatives-hub/interpreting-ich-e6r3/ 

Raise the Line
How Providers Can Join the Battle Against Misinformation: Dr. Raven Baxter, Director of Science Communication at the Cohen Center for Recovery from Complex Chronic Illness

Raise the Line

Play Episode Listen Later May 29, 2025 28:33


We have a special guest on today's episode whose voice will be familiar to regular listeners. Last year at this time, Dr. Raven Baxter occupied the Raise the Line host chair for a special ten-part series we produced in collaboration with the Cohen Center for Recovery from Complex Chronic Illness (CoRe) at Mount Sinai in New York City, where she serves as the Director of Science Communication. The series explored the latest understandings of post-acute infection syndromes -- such as Chronic Lyme and Long COVID -- with an array of experts from the Center and other researchers and providers. In this episode, we check-in with Dr. Baxter to get an update on the work of the Cohen Center, especially with regard to its mission to educate providers. “We're building programs so that clinicians can earn credit for learning about chronic illnesses that are infection associated, and we've also developed a 200-page provider manual. I really think that we will be able to shift the narrative that currently exists,” Dr. Baxter tells host Michael Carrese. That narrative includes lingering skepticism among providers of some infection-associated illnesses, which Dr. Baxter witnessed herself as a Long COVID patient, an experience that has added meaningful perspective to her work. Dr. Baxter is also working on her own time to advance knowledge and combat misinformation through a robust social media presence as “The Science Maven” and helps other scientists and clinicians to do the same. "If we're not there to fill in that void, other people will fill it for us and the narrative may not be consistent with the truth or facts." This is a great opportunity to learn about the art and science of communications that can reach clinicians and patients alike.Mentioned in this episode:Cohen Center for Recovery from Complex Chronic IllnessThe Science Maven If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Conversations in Drug Development
From Lab to Launch – Avoiding the Pitfalls of Drug Development

Conversations in Drug Development

Play Episode Listen Later May 29, 2025 28:04 Transcription Available


In this episode, Dr Neil Fish and Dr Ami Patel dive into the real-world challenges of drug development - from early-stage planning to regulatory hurdles and everything in between. Drawing on decades of experience, they share personal stories and expert insights that reveal why a solid strategy and the ability to pivot are essential for success. They explore the value of strategic flexibility, the importance of engaging with regulators early, and how to approach patent protection and manufacturing for advanced therapies. Whether you're preparing an IND or planning scale-up, this episode delivers clear, actionable guidance grounded in industry know-how. A must-listen for biotech teams, clinical leads, and anyone involved in the drug development process.

Tiny Matters
Ozempic: The science behind this blockbuster drug and its untapped potential

Tiny Matters

Play Episode Listen Later May 28, 2025 26:00


In December 2017, the FDA approved a new injectable drug to treat type 2 diabetes called semaglutide, which you likely know by its brand name: Ozempic. A few years later, during the pandemic, Wegovy, a drug with a higher dose of the same active ingredient, was approved specifically for chronic weight management. Soon after, people taking Ozempic started reporting a dramatic, even “life-changing” weight loss. Ozempic is now a bona fide blockbuster. So what's the science behind these “wonder drugs” that apparently 1 in 10 of us could end up using? They have the potential to have so many positive effects on our lives, from treating Alzheimer's disease and addiction to changing our relationship with consumption but, like with most things, they also come with risks.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma Intelligence Podcasts
FDA in Transition: How Regulatory Shifts Are Redefining Drug Development

Pharma Intelligence Podcasts

Play Episode Listen Later May 27, 2025 13:50


The uncertainty surrounding changes at the FDA and other market dynamics is reshaping the global drug development landscape. In this webinar, CRO regulatory leaders will summarize the collective experience of the biotech companies we've spoken to recently. We will explore: • The impact of the FDA leadership changes, staffing cuts, and return to office mandates in reshaping regulatory priorities. • Trends we're observing from biotech sponsors on the decision of whether or not to keep trials in the US. • The broader implications for industry investment, pipeline prioritization strategies, and international responses. This episode is part 1 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we'll continue exploring the key forces shaping the future of clinical trials.

ACRO's Good Clinical Podcast
S3: E6 From Protocol to Patient: Strategic Uses of AI in Today's Clinical Development

ACRO's Good Clinical Podcast

Play Episode Listen Later May 27, 2025 38:56


Malaikannan Sankarasubbu (Chief Technology & AI Officer, Saama) and Jonathan Shough (Chief Information Officer, Parexel) join this week's episode to discuss how the strategic use of AI technologies is transforming clinical development. They dive deeper into which advancements in generative AI have the potential to improve the clinical trial workflow, the integration of AI and predictive analytics in risk assessment processes, and the importance of strong change management strategies when implementing new AI technologies.

Clinical Research Coach
Disrupting Drug Development – Nasha Fitter's Mission to Transform Rare Disease Research

Clinical Research Coach

Play Episode Listen Later May 26, 2025 43:55


In this episode of The Clinical Research Coach, host Leanne Woehlke sits down with trailblazer Nasha Fitter—tech entrepreneur, rare disease advocate, and co-founder of both the FOXG1 Research Foundation and Citizen Health.After Nasha's daughter was diagnosed with FOXG1 syndrome, an ultra-rare neurological disorder, her world shifted. Instead of accepting the limitations of the current research landscape, she took action- building a foundation, galvanizing the scientific community, and redefining what's possible for families facing rare disease.What began as a grassroots foundation now drives innovative drug development, redefines data collection, and challenges the status quo in drug development.In this conversation, Nasha shares:How a small, determined parent community raised $10M and launched a gene therapy programWhy traditional research models fail rare disease patients—and how to fix themThe power of patient-owned data and how platforms like Citizen Health are transforming access and insightsHow to build empathy for families navigating special needsWhat pharma gets wrong (and right) in working with advocacy groupsHer vision for a precision medicine future—starting with ultra-rareThis is a story about courage, creativity, and a more inclusive, patient-driven future of medicine. Nasha's bold vision and action oriented approach will leave you inspired and hopeful.To Find Out More:Nasha Fitterhttps://www.linkedin.com/in/nashafitter/FOXG1 Research Foundation: https://www.foxg1research.org/Citizen Health:https://www.citizen.health/

Dog Cancer Answers
Insider Look at Rabacfosadine (Tanovea) from Shelved Human Drug to Dog Lymphoma Treatment | Dr. Doug Thamm #284

Dog Cancer Answers

Play Episode Listen Later May 26, 2025 50:53


Dr. Doug Thamm discusses the development and use of Tanovea, a drug for treating lymphoma in dogs. He explains the drug's origins, initially researched as a human cancer therapeutic in collaboration with Gilead Sciences, and its transition to veterinary use.   Dr. Thamm provides insights into Tanovea's application, dosage, and effectiveness compared to the CHOP protocol, as well as its potential side effects and other possible uses in different cancer types like multiple myeloma. The episode also delves into related immunotherapy research and personal reflections from Dr. Thamm, a double cancer survivor, on his career choice in veterinary oncology. Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos:  https://www.youtube.com/watch?v=G0iRyKshzq8  Related Links:  Our article on lymphoma: https://www.dogcancer.com/articles/types-of-dog-cancer/lymphoma-in-dogs/  Our article on Tanovea: https://www.dogcancer.com/articles/drugs/tanovea-rabacfosadine-chemotherapy/  Get the facts on dog cancer remission: https://www.dogcancer.com/articles/stats-and-facts/dog-cancer-remission/  Chapters:  00:00 Introduction  00:13 Interview with Dr. Doug Thamm  00:26 The Early Involvement with Tanovea  00:41 Challenges and Discoveries in Drug Development  02:16 Transition from Human to Veterinary Use  02:48 Clinical Trials and Dosage Experiments  06:45 FDA Approval and Practical Use  08:05 Comparing Tanovea and CHOP Protocol  15:23 Exploring Alternative Treatments: Laverdia  18:43 Off-Label Uses and Future Research  23:46 Exploring Tanovea's Effectiveness in Blood Cancers  25:14 Cost Comparison: Tanovea vs. CHOP  26:15 Side Effects of Tanovea  28:47 Pulmonary Fibrosis and Breed-Specific Risks  32:52 Personal Cancer Journeys: Dr. Doug and His Wife  38:23 Debunking Myths About Dog Cancer Treatment  42:24 The Future of Cancer Treatment: Immunotherapy  45:23 Conclusion and Resources    Get to know Dr. Doug Thamm: https://www.dogcancer.com/people/doug-Thammm-v-m-d-diplomate-acvim-oncology/   For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

IDEA Collider
Creating Breakthroughs in Oncology: A Conversation with Susan Galbraith of AstraZeneca

IDEA Collider

Play Episode Listen Later May 25, 2025 43:26


In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.  With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.Chapter Summaries;00:00 Introduction and Guest Welcome00:27 Susan Galbraith's Career Journey02:37 Defining Success in Oncology R&D05:01 Early Phase Drug Development07:09 Digital Health and Patient Experience12:37 Global Collaboration and Innovation15:05 AI and Future of Oncology28:08 Diversity and Inclusion in Clinical Trials33:46 Mentorship and Career Advice37:45 Challenges and Future Outlook in Oncology42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith;LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

ACRO's Good Clinical Podcast
S3: E5 Rethinking Rare: The Future of Rare Disease Research

ACRO's Good Clinical Podcast

Play Episode Listen Later May 20, 2025 26:56


On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today's patients. They dive deeper into the evolution of rare disease patient advocacy groups, why industry must move beyond the hyperfocus on “blockbuster drugs” to make progress in rare disease research, and how advancements in rare disease treatments can benefit the clinical research ecosystem for all.

Talking Precision Medicine
Stéphane Budel, DeciBio | Precision medicine is our future and our fate | TPM podcast #46

Talking Precision Medicine

Play Episode Listen Later May 19, 2025 50:02


Stéphane Budel, founding partner at DeciBio, joins the Talking Precision Medicine Podcast to explore the future of the field. He unpacks how liquid biopsy, multi-omics, and AI are opening new doors for personalized care, why the diagnostics business model is holding innovation back, and what it will take to make complex tech usable for clinicians and patients alike.⁠TPM E46 highlights >⁠⁠⁠⁠⁠⁠⁠⁠Episode 46 links:DeciBioStephane Budel on LinkedInDeciBio's White Paper on AI in Drug Development (with contributions from Rafael Rosengarten)

Ask AI Podcast
E57 How is AI reshaping the work of drug development?

Ask AI Podcast

Play Episode Listen Later May 19, 2025 20:05


Episode 57 of the Ask AI podcast features a conversation with Eric Sigel, a data scientist and biotech innovator with over 20 years of experience.The discussion delves into how artificial intelligence is reshaping the future of scientific research, particularly in drug discovery, but not always at the expected pace or in anticipated ways. Eric shares insights from his work at X-Chem, where he developed the scientific computing and data science infrastructure for their DNA-Encoded Library platform, and at ZebiAI, a spin-off company that applied machine learning to DEL technology and was acquired by Relay Therapeutics. The episode explores the challenges of integrating AI into laboratory workflows, the bottlenecks that persist despite technological advancements, and the evolving skill sets required for scientists to keep pace with AI's rapid evolution. For more details, please visit the episode post.ABOUT ASK AI PODCASTAsk AI is an independent nonprofit that collaborates with volunteers, industry experts, and AI innovators to share free content and resources that help people spot the opportunities and navigate the challenges associated with the increased adoption of artificial intelligence at work. Visit: askai.org

Raise the Line
Advocating for Black Nurses In An Anti-DEI Environment: Dr. Sheldon Fields, President of the National Black Nurses Association

Raise the Line

Play Episode Listen Later May 15, 2025 23:46


On this episode of “Raise the Line” we welcome Dr. Sheldon Fields, a trailblazer in the nursing field and the president of the National Black Nurses Association. In a candid conversation, Dr. Fields shares his inspiring journey from the bedside to becoming a prominent figure in nursing, HIV/AIDS prevention and academia and also shares the challenges he faced as a Black man in a predominantly white and female field. "I fell in love with a profession that has not always loved me back," he tells host Kelsey Lafayette. Dr. Fields brings over thirty years of experience as an educator, researcher, clinician, administrator, consultant, health policy specialist, and entrepreneur to his current role at NBNA, and as the inaugural associate dean for equity and inclusion at the College of Nursing at Penn State University, where he also serves as a research professor. Listeners will find Dr. Fields' insights on navigating a career in healthcare particularly valuable, as he stresses the importance of resilience, continuing education, and mentorship. It's a compelling listen for anyone interested in the intersection of health, policy, and social justice.Mentioned in this episode:National Black Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Tiny Matters
How a little-known vaccine project and decades of HIV research made "Operation Warp Speed" possible

Tiny Matters

Play Episode Listen Later May 14, 2025 36:32


Over the last 200 years or so, vaccines have come a long way, for a number of viruses. We've made so much progress, in fact, that in 2017 scientists began the early stages of vaccine development for some virus families they believed could pose a future pandemic threat. One of those families was Coronaviridae: coronaviruses. Not many people know that before SARS-CoV-2 started making its way into people in 2019, there was already a project underway in the U.S. to create a vaccine for a looming coronavirus (we didn't!), but even that would not have been possible without the decades of vaccine and drug research that came before it, particularly for HIV. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Link to the Tiny Show & Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Three Cartoon Avatars
EP 143: Debunking Healthcare's Biggest Myths with Zach Weinberg and Derek Thompson

Three Cartoon Avatars

Play Episode Listen Later May 13, 2025


In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

Artificial Intelligence in Industry with Daniel Faggella
Leveraging AI for Better Outcomes Across Drug Development - with Patricio La Rosa of Bayer

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later May 13, 2025 33:16


Today's guest is Patricio La Rosa, Head of End-to-End Decision Science at Seed Production Innovation in Bayer Crop Science. With over 20 years of experience developing AI and data science solutions across healthcare and agriculture, Patricio joins Emerj Managing Editor Matthew DeMello to explore how machine learning can drive better outcomes across the drug development lifecycle, from research design to clinical deployment. Patricio discusses how AI is optimizing early trial planning, improving participant engagement, and supporting ethical, human-centered decisions at scale. Drawing lessons from both agriculture and life sciences, he emphasizes the importance of connecting technical models with real-world workflows. The conversation also delves into key barriers to AI adoption in clinical settings, including behavioral friction, model transparency, and challenges in orchestrating decision-making across global teams. Patricio offers a grounded perspective on what it takes to move from experimentation to enterprise impact in AI-driven R&D. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

ACRO's Good Clinical Podcast
S3: E4 Kernels of Wisdom: What Matters Most in Clinical Trial Monitoring

ACRO's Good Clinical Podcast

Play Episode Listen Later May 13, 2025 41:54


What does clinical trial monitoring have in common with growing a field of corn? Amy Kroeplin (PPD™ clinical research business of Thermo Fisher Scientific), Shailesh Madel (ICON plc), and Nicole Stansbury (Premier Research) join the podcast to discuss the importance of risk-based quality management, centralized monitoring, and strategic SDV/SDR sampling strategies. They dive deeper into the unique roles of SDV and SDR, different methods of implementing SDV/SDR sampling strategies, and the industry imperative to increase centralized monitoring adoption.

ACRO's Good Clinical Podcast
S3: E3 Future-Proofing Drug Development: AI, Old Data, and New Rules

ACRO's Good Clinical Podcast

Play Episode Listen Later May 6, 2025 33:10


On this week's episode, Lisa Moneymaker (SVP, Head of Strategic Customer Engagement, Medidata Solutions) and Adam Aten (Legislative & Regulatory Policy Lead, Verily) join the podcast to discuss how the clinical research industry must use insights from the past to better prepare our AI models and other technologies to meet the needs of patients in the present and future. They dive deeper into the role that collaboration between technologists and clinical scientists can play in helping to reduce bias in our AI models, what legislators and regulators should be keeping top of mind as they write new rules of the road for AI and ML, and ACRO's ongoing efforts to promote the responsible use of AI in clinical research.

Raise the Line
Equipping Today's Medical Students to Manage Uncertainty: Professor Katarzyna Taran, Medical University of Łódź

Raise the Line

Play Episode Listen Later May 1, 2025 31:57


We're honored to continue our global tour of medical education today with Professor Katarzyna Taran, MD, PhD, a pioneering interdisciplinary researcher of tumor cell biology, an award winning educator noted for her focus on student engagement, and -- in a first for a Raise the Line guest -- a shooting sports certified coach and referee. As Professor Taran explains to host Michael Carrese, these seemingly disparate professional activities require the same underlying attributes: patience, the ability to overcome barriers, openness and adaptation. She believes those last qualities are especially important for today's medical students to acquire given the accelerated pace of change in healthcare. “They need to be equipped with the ability for critical thinking, to analyze and synthesize, and to search for unconventional solutions.” Professor Taran tries to impart these skills, in addition to the medical and scientific knowledge students must know, through a high level of engagement. “Teaching is relational, so try to be familiar with students' concerns. Talk to them, listen to them and you will become someone they trust.” In this wide-ranging and engaging conversation, Professor Taran also discusses her work as the head of the Laboratory of Isotopic Fractionation in Pathological Processes in Chair of Oncology, the use of neurodidactics in teaching, and the connection between the science of pathology and the future of humans in space. Mentioned in this episode:Medical University of Lodz If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

pharmaphorum Podcast
AI in drug development: The real hurdle is implementation

pharmaphorum Podcast

Play Episode Listen Later May 1, 2025 12:05


It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI. Stelzer discusses the need for greater coordination within the pharmaceutical industry, particularly between life sciences and software engineering and explains how bridging the cultural divide can significantly enhance the adoption of emerging technologies like AI. Of course, the conversation also touches upon the importance of collaboration, which can positively empower pharmaceutical companies to overcome existing challenges and drive significant advancements in drug development. You can listen to episode 176a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

ACRO's Good Clinical Podcast
S3: E2 Centralized Monitoring in Action: Case Studies From the Field

ACRO's Good Clinical Podcast

Play Episode Listen Later Apr 29, 2025 21:46


On this week's episode, host Sophia McLeod is joined by Danilo Branco (Associate Director, Risk Based Quality Management Lead, BeOne Medicines) and Amanda Coogan (Associate Director, Customer Experience, Remarque Systems) to discuss the value of centralized monitoring implementation by sharing case studies from today's clinical trials. They dive deeper into how centralized monitoring can help detect adverse events more quickly and identify underreporting, the benefits of holistically monitoring trial data using centralized monitoring, and how a targeted SDV/SDR sampling strategy can help organizations to conserve resources while maintaining quality and safety.

Rare Disease, Cell & Gene Therapy Weekly RoundUp
Improving Alignment In Drug Development

Rare Disease, Cell & Gene Therapy Weekly RoundUp

Play Episode Listen Later Apr 28, 2025 36:35


In the latest episode of Let's Talk Rare, Owen Bryant & Georgie Rack delve into the world of drug development in rare diseases.They are joined by the brilliant Rob Freishtat, president of Uncommon Cures. Rob brings unique insights on who the key stakeholder are in developing drugs and the many ways that we can bring them together in order to improve and enhance the delivery of much-needed therapies.

Surfing the Nash Tsunami
S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH

Surfing the Nash Tsunami

Play Episode Listen Later Apr 26, 2025 57:17


00:00:00 Surf's Up, Season 6, Episode 6.On April 23, 2024, our colleague and co-founder, Stephen Harrison, passed away suddenly. This week, Surfing the MASH Tsunami remembers Stephen with two of his closest associates and continues our annual MASH Drug Development roundtable held in his honor. 00:00:04:24 - A Deep Dive into Drug Development, Part 2The second portion of the Drug Development roundtable primarily focuses on three key issues. The first, uptake of resmetirom, starts with Naim Alkhouri discussing his experience in the Arizona Liver Health Clinics with over 650 patients in the year since resmetirom was approved and shifts to the various European panelists (Jörn Schattenberg, Louise Campbell and Sven Francque) estimating when it might be approved in their countries and how widely it might be reimbursed.  The second topic, incretin agonists, focuses on exciting prospects for other incretin agonists in development, as well as some semaglutide combination therapies. The third, NIT clinical trials, covers prospects that non-biopsy clinical trials might be approved sometime in the near future.00:16:20 - Remembering Stephen Harrison I: An Interview with Summit Clinical Research CEO Gail HinksonSummit CEO Gail Hinkson joins Roger Green for the first time on SurfingMASH to discuss her business partner. Gail discusses how the two originally formed Pinnacle Clinical Research and how Pinnacle led to Summit. She proceeds to discuss the current size and reach of both Pinnacle and Summit. Focusing on Summit, Gail describes the company as an Integrated Research Organization (IRO), highlighting its distinct role within the MASH firmament. In the final section of the interview, Gail discusses how Stephen's personality, goals, and vision continue to live on at Summit today.00:34:31 - Remembering Stephen Harrison II: An Interview with Naim Alkhouri Announcing That He Is Joining SummitNewly announced Summit Chief Academic Officer Naim Alkhouri joins this episode for a second time, but in a very different role. Naim discusses his personal history with Stephen and what he loved and respected about his "dear friend." He then makes a major announcement: he is joining Summit as Chief Academic Officer. He shares the many elements of this role, particularly his excitement that Summit can become the entity that educates a wide range of healthcare and commercial professionals on what MASH is and how it is treated. The scope of this vision, combined with what Gail discussed, portrays a level of energy, ambition and vision worthy of Stephen Harrison.00:55:55 - ConclusionAs part of this memorial week, Roger Green forgoes the usual business report, which will return next week.

ACRO's Good Clinical Podcast
S3: E1 Minimizing Impact, Maximizing Progress: Environmental Sustainability in Research

ACRO's Good Clinical Podcast

Play Episode Listen Later Apr 22, 2025 28:55


ACRO's Good Clinical Podcast is back for season 3! To kick off the season, host Sophia McLeod is joined by Clare Campbell-Cooper (Global Head, Digital Health and Innovation, Fortrea) and Michael J. Cohen (Sr. Director, Lead, Environmental Sustainability, PPD™ clinical research business of Thermo Fisher Scientific) to discuss the continued evolution of environmental sustainability in clinical research. They dive deeper into how the clinical research industry can use renewable energy to help meet environmental goals, the importance of promoting more environmentally sustainable shipping and logistics practices, and how our industry can decentralize trial elements responsibly to minimize the environmental impact of the clinical supply chain.

Surfing the Nash Tsunami
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis

Surfing the Nash Tsunami

Play Episode Listen Later Apr 22, 2025 24:24


This conversation is the opening segment of SurfingMASH's April discussion, in memory of Stephen A. Harrison, on drug development. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. This opening discussion focuses on exciting advances in one drug class (FGF-21s) and, more broadly, on exploring ways to treat cirrhosis. As Naim points out in his opening comment, these two issues— cirrhosis as a challenge and FGF-21s as a possible solution path —intersect in clear and exciting ways. He notes that the FGF-21 efruxifermin has been reported to have significant improvement in patients with cirrhosis, while the FGF-21 pegozafermin has shared positive results in a small cohort of patients. He also notes that a third FGF-21, efimosfermin alfa, has results in advanced non-cirrhotic MASH that suggest potential for similar efficacy in patients with cirrhosis, but this must be studied and confirmed in clinical trials. He mentions that resmetirom may also be showing signs of efficacy in some patients with cirrhosis. The entire package, he says, is a "game changer."Jörn notes that we are having parallel advances in treatment for advanced, non-cirrhotic patients. Sven concurs and comments that we are seeing effects that are not strictly related to metabolic disease. There is exceptional power that we can demonstrate one-level regression in sicker patients. The three agree that, at the same time, we are seeing cirrhosis trials that will lead to outcomes data; outcomes trials in non-cirrhotic medications may not be far away.Roger asks whether we are making progress in treating patients living with decompensated cirrhosis. Sven discusses what we are learning about treating portal hypertension, which is an important benefit unrelated to fibrosis regression. Simply improving portal hypertension will have an impact on endpoints. Naim points out that some ongoing trials include patients with cirrhosis, including survodutide and belapectin. Louise notes it will require "great P.R." to reverse some of the current perceptions about cirrhosis, but that this is "great." Naim states that even today, we have "a lot to offer" patients with portal hypertension or other symptoms of decompensation. As he concludes, he notes that this is underappreciated today. 

The Uromigos
Episode 407: Drug Development in China: Part 2 of 2

The Uromigos

Play Episode Listen Later Apr 21, 2025 25:21


Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

Surfing the Nash Tsunami
Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies

Surfing the Nash Tsunami

Play Episode Listen Later Apr 18, 2025 69:00


00:00:00 - Surf's Up: Season 6 Episode 5Host Roger Green briefly describes this episode's three sections and introduces Roundtable guests. The Roundtable panel shares groundbreakers. 00:10:39 - Roundtable: A Deep Dive Into Drug Development, Part OneThe opening portion of this month's roundtable centers around two issues: exciting data for FGF-21s and, more generally, treating patients with cirrhosis. Naim Alkhouri sets the tone in his opening comments, which start by focusing on the exciting SYMMETRY data from efruxifermin and then hones in on FGF-21s and resmetirom in cirrhosis. The rest of the conversation features Jörh Schattenberg, Sven Francque and Naim discussing therapies in development for compensated and decompensating cirrhosis.00;24:44 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing ResmetiromNaga joins Roger to discuss the paper Early Experience with resmetirom to treat Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis in a Real-World Setting from his group at Indiana University, which his group authored and Hepatology Communications recently posted. The paper, based on IU Health's experience with its first 113 resmetirom patients, shares the group's practical experience developing processes to work closely with the specialty pharmacies dispensing resmetirom and, finally, concludes that a more engaged patient management strategy might reduce drug discontinuation to a level comparable with clinical trials.  00:47:21 - Expert: Scott Friedman on Gene Therapy, Diversity of Stellate Cell Types, Other Basic Liver ScienceScott and Roger cover a range of basis science topics in a fast-moving 19-minute discussion. It starts with Scott discussing the increasing acceptance that gene therapy is an acceptable way to treat a range of liver diseases, many of which are orphan or ultra-orphan but, in fact, include potential gene therapies for non-cirrhotic MASH and MASH cirrhosis. He notes that in addition to classic gene therapy, which introduces protective gene variants into the systems of patients with the risky variants, gene therapy is now looking to introduce FGF-21 into patients through genetic modification. From there, the conversation covers CAR-T therapy, the increasing ability to identify many different types of stellate cells and the idea that the most effective therapy for eary fibrosis, advanced fibrosis and cirrhosis might require fundamentally different kinds of interventions. The two final elements are the idea that what we now call "MASH" may be several diseases with different etiologies with similar manifestations and a passionate call for all of us to support maintaining NIH funding in whatever ways we can.01:06:45 - Business ReportAs Roger copes with his laryngitis, AI voices deliver an abbreviated business report 

Raise the Line
Using Technology to Build a Global Community of Medical Students: Alfred Collins, Community Specialist at Osmosis from Elsevier

Raise the Line

Play Episode Listen Later Apr 17, 2025 39:12


We like to think of Osmosis from Elsevier as a global community of millions of learners, connected by a desire to serve humanity and an inclination to use a diverse mix of educational resources to help them become excellent healthcare practitioners. On today's episode of Raise the Line, we're going to learn how Osmosis has created an opportunity for hundreds of those students from sixty countries to actually solidify those connections through the Osmosis Health Leadership Initiative (OHLI). Our guide to this effort is Osmosis Community Specialist Alfred Collins, who brings a keen interest in developing tech solutions to power the future of human communication to his work with OHLI.“Technology collapses barriers to communication and to understanding the nuances behind culture, behind global perspectives,” he tells host Lindsey Smith. One example he cites is how OHLI members learn about variations in the way different cultures approach collaboration, an important insight to gain as they head into team-based healthcare environments. OHLI members convene regularly over video sessions to hear from leaders in healthcare and learn about hosting successful on-campus events, among other enriching content.  They also have an opportunity to provide feedback on improving the Osmosis learning platform, and this year they're participating in a “hackathon” aimed at improving the future of healthcare. Tune in to find out more about what the OHLI program offers, how to apply, and how Alfred thinks virtual reality and AI technologies will impact the future of community building. Mentioned in this episode:Osmosis Health Leadership Initiative If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Biotech Bytes: Conversations with Biotechnology / Pharmaceutical IT Leaders
How AI Is Revolutionizing Biotech & Pharma Research With Liran Belenzon

Biotech Bytes: Conversations with Biotechnology / Pharmaceutical IT Leaders

Play Episode Listen Later Apr 17, 2025 26:49 Transcription Available


The Future of AI in Pharma & Biotech Research #aiinbiotech #pharmaresearch #drugdiscovery AI is fundamentally changing the way biotech and pharmaceutical research happens. From analyzing vast datasets to accelerating drug discovery, AI-powered solutions are making labs smarter, faster, and more efficient. But how does it actually work? Please visit our website to get more information: https://swangroup.net/ In this episode, I sit with Liran Belenzon, CEO of BenchSci, to explore how AI reshapes pharmaceutical research. We discuss:✅ The biggest challenges of working with scientific data✅ Why big pharma companies prefer AI-powered platforms over in-house solutions✅ How multimodal AI enhances lab efficiency and accelerates drug developmentLiran also shares his journey from being an MBA student to leading a company that works with 12 of the world's top 20 pharma companies. If you're curious about the intersection of AI, biotech, and research, this episode is a must-watch. Let's talk about the future of AI in biotech. What excites you the most? Let me know in the comments. Links from this episode:✅ Get to know more about Liran Belenzon: https://www.linkedin.com/in/liranbelenzon ✅ Learn more about BenchSci: https://www.benchsci.com ✅ Follow BenchSci for updates on AI in biotech: https://ca.linkedin.com/company/benchsci 

The Uromigos
Episode 406: Drug Development in China: Part 1 of 2

The Uromigos

Play Episode Listen Later Apr 14, 2025 30:02


Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

Surfing the Nash Tsunami
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment

Surfing the Nash Tsunami

Play Episode Listen Later Apr 13, 2025 24:34


This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

Surfing the Nash Tsunami
S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy

Surfing the Nash Tsunami

Play Episode Listen Later Apr 11, 2025 72:42


00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses recent advances in drug development, focusing on agents in Phase 3 trials.00:04:24 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:06:03 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 4This is the concluding portion of our Emerging Trends Conference Roundtable. The group focuses on key lessons they have learned and messages they would like listeners to take from this conversation.  The pivotal idea is that SLD is a spectrum running from MASLD through MetALD to ALD. Researchers and treaters will all do best in developing and implementing therapies and guidelines with this thought in mind. Aleksander Krag stresses this idea and notes that, with several different classes of drugs demonstrating positive impact, it will be an exciting decade ahead as we learn how to apply these drugs along the spectrum. Jenn Jones and Alex Lalos note the importance of identifying MetALD, although Jenn noted that it does not seem wise to conduct trials solely with MetALD patients at this time.  00:22:04 - Newsmaker: Mike Betel on the Increased Visibility of Patient AdvocatesThis week's newsmaker, Mike Betel, has experienced a significant increase in the number of conferences at which he is invited to speak or appear on a panel. This discussion centers around the reasons Mike believes this is happening and the message(s) he delivers. To Mike, his most important contribution lies in the amount of information he sends back from each event, many of which surpass 30% download rates (and some even hit 50%). He discusses his value in diabetes, endocrinology and obesity meetings, where he brings a "liver" perspective and co-education opportunity to these events. The entire experience has taught him about the need not to stigmatize patients and reinforced his belief in the importance of tailoring care to patients' needs and personalities. 00:49:28 - Expert: Mazen Noureddin on the Exciting MASLD Drug Development EnvironmentHepatologist and Key Opinion Leader Mazen Noureddin joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. Specifically, he discusses the FGF-21 agents, the range of patients for whom they might be appropriate, how efruxifermin's 96-week results may make the idea of "induction therapy" less appropriate,  and the exciting early data on cirrhosis patients. He provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. He goes on to discuss the pan-PPAR lanifibranor, the FASN inhibitor denifenstat, and notes ongoing work on new classes and combination therapies. In general, he paints, I think, not a rosy, but an extremely optimistic picture of what the future will be for patients who need to be treated for fatty liver. 01:09:38 - Business Report Roger discusses the next Roundtable and provides some details on SurfingMASH's coverage of the upcoming EASL Congress.

MedEvidence! Truth Behind the Data

MedEvidence! Truth Behind the Data

Play Episode Listen Later Apr 7, 2025 5:57 Transcription Available


Send us a textOn this Monday Morning Minute, Dr. Michael Koren draws parallels between the NCAA Final Four basketball tournament and the clinical research process. He explains that in medicine, researchers start with literally 10,000 potential molecules, which get whittled down to only three or four medications to be tested in big, phase III clinical trials. This ensures that only the most promising medical technologies get approved, just like the most promising teams get to the National Championships.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Raise the Line
Aligning Education Technology With How Students Live and Learn: David Game, SVP of Product Management, Global Medical Education at Elsevier

Raise the Line

Play Episode Listen Later Apr 3, 2025 28:37


David Game remembers the days when the use of digital technology in education publishing amounted to putting a dictionary on a compact disc. Now, as the senior vice president of Product Management, Global Medical Education at Elsevier, he oversees a suite of learning materials that use artificial intelligence, virtual reality and 3-D modeling. “We've expanded into immersive technology with Apple Vision Pro that enables you to be inside the human body, to see and explore the human heart from the inside out and it is absolutely stunning,” says Game, whose long career in publishing includes experience in North America, the United Kingdom, Europe, China and India. As Game has witnessed first-hand, advancements in ed tech, including distance learning, have provided students with an array of options and modalities to choose from that accommodate different learning styles and life circumstances, and that puts a premium on being able to meet students where they are. “We want to make sure that students find learning from our materials engaging, efficient, and aligned with how they live their lives and do their work.” Join host Lindsey Smith for this fascinating episode of Raise the Line to learn how Elsevier is leveraging the innovations offered by Osmosis, Complete Anatomy and ClinicalKey Student to enrich the learning of medical students on their journey to becoming excellent clinicians.Mentioned in this Episode:Complete AnatomyClinicalKey StudentOsmosis If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

DG Early-Morning Show
The Future of Drug Development: 3D Vascularized Tissue Models in Clinical Trials

DG Early-Morning Show

Play Episode Listen Later Apr 1, 2025 38:24


In this episode, I talked to Dr. Karolina Valente, CEO of Voxcell BioInnovation. Dr. Valente talks about how her company, Voxcell, is trying to revolutionize the drug development process by developing customizable 3D tissue models to test different therapeutics and drugs. We also talked about how AI will affect future drug trials, Vancouver's potential as a biotech hub, improvements needed to strengthen Canada's biotech industry, Voxcell's new and old products, and the difficulty of raising money to go to different rounds. ---------------------------------------------------------------Thanks to the sponsors:Audible: Use my link for a 30-day free trial: http://audibletrial.com/diamondgoatNewsly: https://newsly.mepromo code to receive a 1-month free premium subscription: EARLYMORNING Libysn: https://libsyn.compromo code: DG Dubby Energy: https://www.dubby.ggpromo code for 10% off: DIAMONDGOATOpus Clips:  https://www.opus.pro/?via=diamondgoat----------------------------------------------------------------------------------Listen on:Podcast website: https://www.spreaker.com/podcast/dg-early-morning-show--5943922Spotify: https://open.spotify.com/show/0EuhA6WyuerHtVAqcFrFeOPodcast YT channel clips: https://www.youtube.com/@dgearlymorningshowTiktok: @dgearlymorningshowApple Podcast: https://podcasts.apple.com/us/podcast/dg-early-morning-show/id1575451533Amazon Music: https://music.amazon.com/podcasts/f050b86c-1dad-4bc3-b12f-6aa5fa62438c  Goodpods: https://goodpods.com/podcasts/dg-early-morning-show-211830RadioPublic: https://radiopublic.com/dg-earlymorning-show-WoML4rBreaker: https://www.breaker.audio/dg-early-morning-showReason: https://reason.fm/podcast/dg-earlymorning-show--------------------------------------Check out my other stuff:Instagram: @itzdiamondgoatTwitter: @lildiamondgoatMain YT channel: youtube.com/diamondgoatTiktok: @lildiamondgoatSoundcloud: @Lil DiamondgoatSpotify: @Lil DiamondgoatMerch store: https://diamondgoat.creator-spring.com

Vanguards of Health Care by Bloomberg Intelligence
Model Medicines AI Drug Development

Vanguards of Health Care by Bloomberg Intelligence

Play Episode Listen Later Apr 1, 2025 74:50 Transcription Available


“We didn’t start Model to launch a company — we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health Care, Haders speaks with Bloomberg Intelligence analyst Andrew Galler about building an AI-native drug discovery engine capable of identifying cryptic binding pockets and designing first-in-class drugs. They unpack why hit rates and novelty must go hand-in-hand, an overview of the company’s pan-antiviral MDL-001, and why generalizability — not reinforcement learning — is the true litmus test for AI in biotech.See omnystudio.com/listener for privacy information.

The EMG GOLD Podcast
S09 E09: Boehringer's Christoph von der Goltz on setbacks and success in R&D

The EMG GOLD Podcast

Play Episode Listen Later Apr 1, 2025 22:08


How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week's episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.  Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.  A little more on EMJ GOLD's guest…  Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden. 

Raise the Line
Helping All Medical Providers Understand Genomic Testing: Dr. Ethylin Wang Jabs, Mayo Clinic and Dr. Antonie Kline, Harvey Institute for Human Genetics

Raise the Line

Play Episode Listen Later Mar 20, 2025 16:06


An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

CNBC's
International Investing Vs. U.S… And NIH Funding Cuts Impact On Drug Development 3/17/25

CNBC's "Fast Money"

Play Episode Listen Later Mar 17, 2025 43:45


International markets have outperformed the U.S. in a big way this year, but will the trend continue into Q2? Where are out traders see the biggest global gains, and if they're betting on more divergence between the markets. Plus NIH funding cuts putting drug development on the chopping block. The names feeling the impact, and what's at stake in the pharma space.Fast Money Disclaimer

TechSurge: The Deep Tech Podcast
Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet

TechSurge: The Deep Tech Podcast

Play Episode Listen Later Mar 13, 2025 41:44


Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis' unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.Links:Explore Prellis Biologicshttps://prellisbio.com/Understand AlphaFold, DeepMind's AI model for predicting protein structureshttps://deepmind.google/alphafoldRead about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/ 

Inside the ICE House
February 2025 Rewind: "Best of" Inside the ICE House

Inside the ICE House

Play Episode Listen Later Feb 26, 2025 15:35


In February, the Inside the ICE House Podcasts aired four new episodes covering a diverse range of industries, from the development of ICE Voice and the changing workforce, to the rebranding of an insurance industry icon and how AI is helping in drug development. Episode 456: IPC Systems CEO Kurt Adams on Innovation, Acquisition, & the Development of ICE Voice Episode 457: Author Rishad Tobaccowala on Retraining, Relearning, and "Rethinking Work" Episode 458: Novartis CEO Vas Narasimhan on Drug Development & AI's Role in Disease Treatment Episode 459: The Hartford's Chris Swift & Claire Burns on Legacy, A Bold New Look, and Lasting Impact

Outcomes Rocket
Human Insight Plus AI: A Winning Combination For Drug Development with Liesbeth Ceelen, CEO, and Arjan van Manen, Commercial Director of BioLizard

Outcomes Rocket

Play Episode Listen Later Feb 26, 2025 6:57


This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com The crucial combination of human expertise and AI is paramount for success in drug development.  In this episode, Liesbeth Ceelen, CEO, and Arjan van Manen, Commercial Director of BioLizard, discuss the critical role of data analytics and machine learning in the pharmaceutical industry, highlighting the increasing need for companies to become data-driven. They emphasize how a deep understanding of biology, supported by AI, can optimize target discovery and reduce clinical trial failures. BioLizard offers the expertise and a platform to support biotech and pharma companies in this new data-driven approach as the industry shifts from viewing data analysis as a cost to a necessity for better outcomes. Finally, they touch upon predictions for 2025, focusing on a more data-supported approach to drug development, tailored treatments, and a heightened focus on target mechanisms while remaining optimistic about the changing mindset of industry stakeholders. Tune in and learn how data analytics can transform your approach to drug development! Resources:  Connect and follow Liesbeth Ceelen on LinkedIn. Follow and connect with Arjan van Manen on LinkedIn. Follow BioLizard on LinkedIn and visit their website. Discover more about BioLizard's platform, BioVerse, here. Fast Track Your Business Growth: Outcomes Rocket is a full service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com